Suppression of pathergy in pyoderma gangrenosum with infliximab allowing for successful tendon debridement

Pyoderma gangrenosum (PG) is an inflammatory condition that causes neutrophilic infiltration of the skin and characteristic skin ulceration.1 More than half of patients develop PG in association with an underlying systemic disease.1 Its pathophysiology is complicated and not fully understood.1 PG can affect any part of the body, but it commonly affects the legs.2 The diagnosis of PG can be challenging and is often one of exclusion.3 PG exhibits pathergy, which is the development or worsening of a lesion at the site of trauma, and the presence of pathergy can help support the diagnosis of PG.